Retatrutide's data was built on obese patients. Lean athletes are dosing blind.
Retatrutide produced the largest weight-loss result in the GLP-1 class: 28.3% of body weight gone at 80 weeks on 12 mg, with almost half of participants losing more than 30% (phase 3, reported May 2026). That number is why it keeps showing up in performance and longevity circles.
Here is the part those circles skip. Every one of those patients had obesity. The trials were built, dosed, and measured on high-BMI bodies chasing weight loss. If you are lean, training hard, and reaching for reta for a performance edge, you are not a lighter version of the trial patient. You are a population the data has never looked at.
The endpoint was weight, not what you care about
The reta trials measured total body weight dropping. For a patient with 100 lbs to lose, that is the whole game. For a lean athlete, weight going down is not the win. Keeping lean mass while it happens is.
On that axis reta looks worse than the drugs it beats on the scale. The 2025 Lancet body-composition substudy found participants on 8 mg and 12 mg lost 6.5 to 6.9 kg of lean mass over 36 weeks, roughly 37 to 40% of everything they lost. Tirzepatide's comparable figure is about 25%. Reta loses more total weight, and a higher share of that weight is muscle.
The mechanism backs the data. Reta's third receptor is glucagon, and the common assumption that glucagon spares muscle is wrong. Glucagon is catabolic: it breaks down both fat and muscle for fuel. GLP-1 and GIP look more muscle-favorable; glucagon is the lever that adds the extra burn and the extra lean-mass cost at the same time.
For someone whose entire goal is holding or building muscle, that reads as the compound working against the goal, not a side effect to titrate away.
The dose ladder was never built for you
The reta ramp runs 1, 2, 4, 8, then 12 mg in roughly monthly steps (phase 2, Jastreboff NEJM 2023). That ladder exists to walk a patient with obesity up to a weight-loss dose their gut can tolerate. The first therapeutic rung sits around 5 mg.
None of that maps to a lean user who wants a light metabolic or longevity effect without the muscle hit. The microdose figures that circulate, roughly 0.25 to 0.5 mg, are mechanism-based extrapolation. There is no validated human outcome data at sub-therapeutic reta doses. And reta itself is still investigational: it is not an approved drug in the US or the EU.
So the performance user who hits a lean-mass or energy decline in week one has nothing to correct against. There is no lean-athlete dose, no lean-athlete titration schedule, no lean-athlete endpoint in any trial. The guidance does not exist yet.
The side-effect map lands harder on a lean body
The tolerability numbers were also collected on high-BMI patients: nausea in 40 to 45% at the top dose, resting heart rate up 6.7 bpm at the top dose, and dysesthesia (skin tingling) in 1 in 8 to 1 in 5 patients at 12 mg. A sustained resting-HR increase of that size is associated with worse cardiovascular outcomes across nearly every population studied, though the long-term reta-specific data does not exist yet.
Layer that onto an athlete who already trains at an elevated heart rate and often sits in a caloric deficit, and the same signals stack on a body with far less margin than the trial population had.
What the honest answer usually is
For most lean performance users, reta is not a dosing puzzle to solve. It is the wrong product.
Our own clinical routing sends the lean optimizer, someone lean and healthy chasing muscle and longevity, toward the growth-hormone and IGF axis, and routes reta out: it is the highest lean-mass-loss agent in the class, which fits a higher-BMI weight-loss goal (BMI 30 and up), not a muscle goal. Max Marchione's widely shared GLP-1 menu lands in the same place: 100 lbs to lose points to reta, already lean and after longevity points to a tirzepatide microdose at most.
If someone does run it with a clinician anyway, the guardrails a clinician watches are specific. DEXA to track lean mass. A hard stop on advancing the dose if lean mass falls past 25 to 30% of total loss, or if grip and strength drop. A protein floor around 1.8 to 2.0 g/kg to defend muscle. Wearable heart rate watched from the first injection. Those are the clinician's stop criteria, not a protocol to self-run.
The week-1 split decline a performance user reports is not a titration error. It is the drug doing what it does, to a body that had no fat to spare.
If you are trying to separate what a compound is doing to you from what your training is doing, start with a baseline and one variable at a time: how we think about vetting a source and a protocol. More across the class on the feed, plus the maintenance version of this same gap in Retatrutide worked. Now what? and the clinic stack that came with no dosing protocol.